MEETING REPORT

JOINT WHO/UNAIDS ANNUAL CONSULTATION WITH PHARMACEUTICAL COMPANIES AND STAKEHOLDERS ON FORECASTING GLOBAL DEMAND OF ANTIRETROVIRAL DRUGS FOR 2013–2016

25-26 NOVEMBER 2013, GENEVA, SWITZERLAND

MARCH 2014
CONTENTS

LIST OF ABBREVIATIONS AND ACRONYMS 6

1. INTRODUCTION 7

2. MEETING SESSIONS 8

SESSION I. ACHIEVING UNIVERSAL ACCESS: GLOBAL GUIDANCE FOR INNOVATION 8
    Discussion 8
    Suggestions from the discussion 8
SESSION II. FORECASTS OF GLOBAL ARV DEMAND 2013–2016 9
    Comments by ARV Demand Forecasting Technical Working Group members 10
    Suggestions from the discussion 11
SESSION III. FORECASTS OF GLOBAL PAEDIATRIC ARV DEMAND 2013–2016 14
    Suggestions from the discussion 22
SESSION IV. PANEL DISCUSSION ON ADDRESSING CHALLENGES OF PROCUREMENT AND SUPPLY CHAIN MANAGEMENT TO IMPROVE ACCESS TO ARVS: REGULATIONS, FINANCIAL RESOURCES AND PROCUREMENT MECHANISMS 15
    Suggestions from the discussion 16
SESSION V. LOOKING FORWARD 16
    Suggestions from the discussion 17

ANNEX I. FINAL AGENDA 18

ANNEX II. LIST OF PARTICIPANTS 21
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC</td>
<td>abacavir</td>
</tr>
<tr>
<td>API</td>
<td>active pharmaceutical ingredient</td>
</tr>
<tr>
<td>ART</td>
<td>antiretroviral therapy</td>
</tr>
<tr>
<td>ARV</td>
<td>antiretroviral</td>
</tr>
<tr>
<td>ATV</td>
<td>atazanavir</td>
</tr>
<tr>
<td>AZT</td>
<td>zidovudine</td>
</tr>
<tr>
<td>CD4</td>
<td>cluster of differentiation 4</td>
</tr>
<tr>
<td>CHAI</td>
<td>Clinton Health Access Initiative</td>
</tr>
<tr>
<td>ddl</td>
<td>didanosine</td>
</tr>
<tr>
<td>d4T</td>
<td>stavudine</td>
</tr>
<tr>
<td>DRV</td>
<td>darunavir</td>
</tr>
<tr>
<td>DTG</td>
<td>dolutegravir</td>
</tr>
<tr>
<td>Global Fund</td>
<td>Global Fund to Fight AIDS, Tuberculosis and Malaria</td>
</tr>
<tr>
<td>GPRM</td>
<td>Global Price Reporting Mechanism</td>
</tr>
<tr>
<td>EFV</td>
<td>efavirenz</td>
</tr>
<tr>
<td>ETV</td>
<td>etravirine</td>
</tr>
<tr>
<td>FDC</td>
<td>fixed-dose combination</td>
</tr>
<tr>
<td>3TC</td>
<td>lamivudine</td>
</tr>
<tr>
<td>USFDA</td>
<td>United States Food and Drug Administration</td>
</tr>
<tr>
<td>FDC</td>
<td>fixed-dose combination</td>
</tr>
<tr>
<td>FTC</td>
<td>emtricitabine</td>
</tr>
<tr>
<td>IATT</td>
<td>Inter-Agency Task Team for the Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Children</td>
</tr>
<tr>
<td>IDV</td>
<td>indinavir</td>
</tr>
<tr>
<td>LPV/r</td>
<td>lopinavir/ritonavir</td>
</tr>
<tr>
<td>NNRTI</td>
<td>non-nucleoside reverse-transcriptase inhibitors</td>
</tr>
<tr>
<td>NRTI</td>
<td>nucleoside reverse-transcriptase inhibitors</td>
</tr>
<tr>
<td>NVP</td>
<td>nevirapine</td>
</tr>
<tr>
<td>OGAC</td>
<td>Office of the U.S. Global AIDS Coordinator</td>
</tr>
<tr>
<td>OTIF</td>
<td>on time and in full</td>
</tr>
<tr>
<td>PEPFAR</td>
<td>U.S. President’s Emergency Plan for AIDS Relief</td>
</tr>
<tr>
<td>PI</td>
<td>protease inhibitor</td>
</tr>
<tr>
<td>PMTCT</td>
<td>prevention of mother-to-child transmission</td>
</tr>
<tr>
<td>RAL</td>
<td>raltegravir</td>
</tr>
<tr>
<td>RTV</td>
<td>ritonavir</td>
</tr>
<tr>
<td>SCMS</td>
<td>Supply Chain Management System</td>
</tr>
<tr>
<td>SQV</td>
<td>saquinavir</td>
</tr>
<tr>
<td>TAF</td>
<td>tenofovir alafenamide</td>
</tr>
<tr>
<td>TDF</td>
<td>tenofovir disoproxil fumarate</td>
</tr>
<tr>
<td>UNAIDS</td>
<td>Joint United Nations Programme on HIV/AIDS</td>
</tr>
<tr>
<td>UNICEF</td>
<td>United Nations Children’s Fund</td>
</tr>
<tr>
<td>USAID</td>
<td>United States Agency for International Development</td>
</tr>
<tr>
<td>VL</td>
<td>viral load</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>XTC</td>
<td>lamivudine or emtricitabine</td>
</tr>
<tr>
<td>ZDV</td>
<td>zidovudine (AZT)</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

The World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) Secretariat jointly organized an annual two-day consultation with pharmaceutical companies and stakeholders to present them with the draft forecasts for the demand of antiretroviral (ARV) drugs in 2013–2016. These forecasts were prepared in collaboration with the Clinton Health Access Initiative (CHAI), Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), Office of the U.S. Global AIDS Coordinator (OGAC), Supply Chain Management System (SCMS), UNAIDS, United Nations Children’s Fund (UNICEF), United States Agency for International Development (USAID) and WHO, supported by the Futures Institute. The consultation was held on 25–26 November 2013 in Geneva, Switzerland, and gathered 70 participants from the innovator and generic drug industry, active pharmaceutical ingredient (API) producers, professionals from partner organizations, a representative from the National Department of Health, South Africa, and civil society and other nongovernmental organizations.

The opening remarks were delivered by Hiroki Nakatani (Assistant Director-General, HIV/AIDS, TB, Malaria and Neglected Tropical Diseases, WHO) and by Mariângela Simão (Director of Rights, Gender, Prevention and Community Mobilization Department, UNAIDS). In his opening remarks, Hiroki Nakatani noted the importance of the meeting on global ARV demand forecasts to prevent stock outs while the international community is scaling up access to ARV treatment towards the objective of 15 million people on antiretroviral therapy (ART) by 2015. He thanked the ARV Demand Forecasting Technical Working Group for coordinating efforts to produce global ARV demand forecast figures that were going to be discussed. He welcomed all participants and expressed his gratitude to UNAIDS for the effective collaboration on this project.

Mariângela Simão welcomed the participants and spoke about the inequalities in access to care and treatment, especially in key populations and children. The pillars of Treatment 2.0, on which UNAIDS is focused, were elaborated in her speech and she noted that with treatment optimization, better paediatric formulations and increased domestic funding, the target of 15 million people on ART by 2015 will be achieved.

Joseph Perriëns (Coordinator, HIV Technologies and Commodities, WHO) introduced the following objectives of the consultation meeting:

- present an update on ART coverage and on the impact of the 2013 WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection;
- present and discuss ARV market trends and global demand forecasts for 2013–2016;
- present and discuss the situation on domestic and international financial resources for ARVs.

This report summarizes the main points discussed during the meeting. The agenda and list of participants are found in Annexes I and II.
2. MEETING SESSIONS

This report is focused on the discussions that followed the presentations. The presentations can be accessed on the following Dropbox link: https://www.dropbox.com/sh/tyg0i07ub0dttfb/9mje5fuhaq?n=37718888

Session I. Achieving universal access: global guidance for innovation

Chaired by Joseph Perriëns (Coordinator, HIV Technologies and Commodities, WHO), this session covered an overview of the 2013 WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, and an update on the UNAIDS Treatment 2015 Initiative.

Meg Doherty (Coordinator, HIV Treatment and Care, WHO) highlighted the 2013 WHO consolidated guidelines for HIV treatment and prevention. She noted that 9.7 million people were on ART at the end of 2012, or 61% coverage overall before the new WHO guidelines. The new eligibility criteria increased the number of people eligible for ART to 28.6 million. This increase of denominator reduces the ART coverage but it is a great opportunity to accelerate the number of people on ART. She expressed the need to prioritize treatment for paediatrics because ARV coverage rates are disproportionately lower for children (34%) compared with adults. The impact of the 2013 WHO consolidated guidelines has resulted in two major outputs: increased uptake of tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine [FTC] + efavirenz [EFV], which is the preferred first-line regimen, and accelerated phase out of stavudine (d4T)-based regimens.

Badara Samb (Chief, Global Outreach and Special Initiatives, UNAIDS) voiced the need to expand ART coverage faster than it is today by incorporating three new concepts: speed, focus and innovation. These concepts are necessary, as an additional 5 million people have to be on treatment in 2 years from now in order to achieve the target of having 15 million people on treatment by 2015. A major challenge encountered is that many people do not have access to ART as a result of the distance to a health facility. In order to scale-up ARV treatment faster, we need to be innovative and to:

- focus on where greater impact is expected to occur: key populations, high prevalence populations or countries, high-risk groups in low-prevalence countries;
- increase the proximity of service delivery to improve access: task shifting, the involvement of the community;
- UNAIDS is committed to:
  - motivating policy-makers to extend treatment to those who are missed out;
  - generating increased demand for treatment, equity and helping mobilize resources for treatment;
  - promoting country-level commitment;
  - monitoring and reporting on progress.

Discussion

Participants asked about the increase in number of people eligible for ART if we moved to the test and treat approach. They also asked how to prioritize transition from current practice to new guidelines and how to be innovative as, in their view, the health systems are already overstretched with the current number of people in need of ART. Meg Doherty responded that the number of people eligible for ARV treatment would increase from 28.6 million to 32 million if we moved to “test and treat”. However, there is as yet insufficient evidence that would lead to such a recommendation by WHO. Regarding innovation to deal with health system constraints, community involvement in ART and task-shifting are supported by WHO and should be considered.

Suggestions from the discussion

- Use more community involvement, task shifting and public–private partnership.
- Prioritize and focus on where quick wins can be made, in particular in high-prevalence countries and in the most at-risk key populations.
- Treatment should be seen as an investment rather than as a cost to countries and international community, as it contributes to prevention.
- Countries to expand access to CD4 and viral load monitoring services to ensure good-quality ART services and timely switch to second-line ART.
- Use treatment optimization: one fixed-dose combination (FDC) pill a day; less regimens in national ART programmes; efficiency in procurement and delivery of ART services; well-planned transitioning to new regimens. A policy brief has been developed on the transition to new ARV treatment regimens: http://apps.who.int/iris/bitstream/10665/104449/1/WHO-HIV-2014.4_eng.pdf and this will be updated in 2014.
- Patients on d4T-based regimens should be switched to TDF-based regimens.
Session II. Forecasts of global ARV demand 2013–2016

Chaired by Joseph Perriëns (Coordinator, HIV Technologies and Commodities, WHO), the second session was opened with three presentations:

1. Vincent Habiyambere (HIV Technologies and Commodities, WHO) presented the results of the 2013 WHO survey on ARV use for adults, including trends of regimens and APIs since 2006. The results presented from a sample of 96 low- and middle-income countries (6.2 million people on ART at the end of 2012) revealed that the use of d4T was decreasing significantly and TDF-based regimens were increasing (Fig. 1). The trend analysis revealed that TDF increased from less than 1% at the end of 2006 to 36% at the end of 2012; d4T-based regimens decreased in the same period from almost 70% to 19%; and zidovudine (AZT)-based regimens increased from 29% in 2006 to 44% in 2012. This trend will continue. The number of first-line ART regimens in use is still high in several countries and the proportion of patients on second-line ART regimens is still low. Details of this survey will be published in 2014.

2. Boniface Dongmo-Nguimfack (HIV Technologies and Commodities, WHO) presented on the uptake of different ARV adult formulations from the Global Price Reporting Mechanism (GPRM) database. In 2013, the market share of TDF increased to slightly over 60% and d4T sales dropped to less than 3% (Fig. 2).

Figure 1. Evolution in the use of APIs in adults, 2006–2013

Figure 2. Market share per API for nucleoside reverse transcriptase inhibitors
3. Global ARV demand forecasts were presented by John Stover (Vice President, Futures Institute) on behalf of the ARV Demand Forecasting Technical Working Group. The forecasts are based on data obtained from: the annual WHO survey on ARV use; transaction data from the GPRM database; CHAI projections; UNAIDS estimates of need for ART; and SCMS and Global Fund quantification data for 2014 and 2015. Three different approaches were used to produce the forecasts: linear extrapolation; country targets; and CHAI projections in 21 high-burden countries. Based on these methods, it is projected that the “15 by 15” target will be achieved, and 16.8 million people will be on ART by 2016. The volume of ARV demand was forecasted and discussed with pharmaceutical industry and partners. The updated data are presented in Fig. 3 and Fig. 4.

**Figure 3. Projected numbers of patients on ART: adults and children. Country targets, linear and CHAI projections**

![graph showing projected numbers of patients on ART](image)

**Figure 4. Volume of demand for ARVs (person-years).**

Country target projections for ATV, atazanavir; EFV, efavirenz; FTC, emtricitabine; 3TC, lamivudine; LPV, lopinavir; NVP, nevirapine; d4T, stavudine; RTV, ritonavir; TDF, tenofovir; ZDV, zidovudine

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>d4T</td>
<td>2,184,916</td>
<td>2,346,782</td>
<td>2,483,444</td>
<td>2,275,078</td>
<td>1,325,147</td>
<td>888,475</td>
<td>597,666</td>
<td>556,514</td>
<td>457,666</td>
</tr>
<tr>
<td>ZTD</td>
<td>1,459,080</td>
<td>1,667,437</td>
<td>2,340,551</td>
<td>2,960,099</td>
<td>4,121,762</td>
<td>4,379,451</td>
<td>5,215,481</td>
<td>6,163,919</td>
<td>7,064,711</td>
</tr>
<tr>
<td>TDF</td>
<td>327,869</td>
<td>366,573</td>
<td>796,197</td>
<td>1,660,226</td>
<td>2,464,062</td>
<td>4,872,593</td>
<td>7,352,937</td>
<td>9,451,619</td>
<td>11,390,251</td>
</tr>
<tr>
<td>3TC</td>
<td>3,732,573</td>
<td>4,140,420</td>
<td>5,330,124</td>
<td>5,324,809</td>
<td>7,339,583</td>
<td>8,932,521</td>
<td>10,115,009</td>
<td>11,106,918</td>
<td>12,218,110</td>
</tr>
<tr>
<td>NVP</td>
<td>2,162,104</td>
<td>2,461,372</td>
<td>3,201,530</td>
<td>3,979,716</td>
<td>4,694,176</td>
<td>5,133,884</td>
<td>5,500,077</td>
<td>5,964,335</td>
<td>6,243,319</td>
</tr>
<tr>
<td>EFV</td>
<td>1,584,866</td>
<td>1,695,161</td>
<td>2,145,304</td>
<td>2,665,055</td>
<td>3,009,470</td>
<td>4,448,701</td>
<td>6,158,023</td>
<td>7,831,870</td>
<td>9,639,298</td>
</tr>
<tr>
<td>FTC</td>
<td>194,072</td>
<td>227,949</td>
<td>303,433</td>
<td>464,336</td>
<td>846,388</td>
<td>1,446,574</td>
<td>2,444,667</td>
<td>3,551,132</td>
<td>4,543,409</td>
</tr>
<tr>
<td>LPV</td>
<td>191,830</td>
<td>216,375</td>
<td>279,909</td>
<td>360,332</td>
<td>462,512</td>
<td>770,373</td>
<td>983,919</td>
<td>1,237,221</td>
<td>1,500,623</td>
</tr>
<tr>
<td>ATV</td>
<td>34,123</td>
<td>35,463</td>
<td>30,557</td>
<td>10,123</td>
<td>30,383</td>
<td>89,299</td>
<td>174,171</td>
<td>269,791</td>
<td>392,916</td>
</tr>
<tr>
<td>RTV</td>
<td>179,137</td>
<td>214,442</td>
<td>197,263</td>
<td>329,933</td>
<td>481,426</td>
<td>881,064</td>
<td>1,272,501</td>
<td>1,692,611</td>
<td>2,155,836</td>
</tr>
<tr>
<td>Other</td>
<td>164,218</td>
<td>171,617</td>
<td>199,549</td>
<td>232,562</td>
<td>261,216</td>
<td>466,447</td>
<td>658,235</td>
<td>841,390</td>
<td>1,068,775</td>
</tr>
</tbody>
</table>

**Comments by ARV Demand Forecasting Technical Working Group members**

CHAI noted that their projections did not take into account the new WHO guidelines, which may affect CHAI projections in the future.

SCMS noted that third-line regimens need to be considered in the future and some formulations used in third-line regimens should be featured in the projections, even if their proportion is small. Their projection would be used in advocacy for maintaining their production.

These forecasts are critical to the work of the Medicines Patent Pool, as they are used for negotiating licences.
Suggestions from the discussion

• The continued production of forecasts of global ARV demand was welcomed and called for.
• The international community should continue its support to countries to reach their ART targets.
• A pooled procurement approach and early submission of orders should be adopted for low-volume products such as paediatric ART and second-line/third-line regimens.
• Modelling for new ARVs and products in the pipeline was also recommended for future forecasts. Factors to take into account include: U.S. Food and Drug Administration (FDA) approval; better efficacy and safety profiles; price evolution; changes in WHO and national guidelines; and national registration. Without these elements in place, the market for new products would remain low.
• Increasing access to viral load for early detection of treatment failure was recommended to increase the proportion of people on second-line ART. South Africa confirmed that access to a good laboratory network is an important factor explaining the high proportion of people on second-line ART observed in South Africa.
• Future forecasts of API demand should take into account the scenarios on the uptake of the new guidelines, and the availability of new diagnostics and new formulations.
• The capacity to produce TDF- and EFV-based formulations has increased and is sufficient to serve the demand but procurement practices need to be improved; for instance, placing orders ahead of time and using pooled procurement.

• Forecasting not only API uptake but also ARV formulations should be considered.

Session III. Forecasts of global paediatric ARV demand 2013–2016

Chaired by Joseph Perriëns (Coordinator, HIV Technologies and Commodities, WHO), the third session was opened with four presentations:

1. David Jamieson (Deputy Director, SCMS) presented the optimal paediatric ARV formulary proposed by the Inter-Agency Task Team for the Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Children (IATT). He noted that the present procurement is highly fragmented and explained that the reason for developing the optimal paediatric ARV formulary was to rationalize national procurement and reduce fragmentation of regimens. The formulary has three groups of ARV formulations:
• optimal paediatric ARV formulary: the minimum number of ARV formulations needed to provide all currently recommended, preferred and alternative first- and second-line WHO-recommended regimens for all paediatric weight bands;
• limited-use paediatric ARV formulary: formulations that may be needed during transition and for special circumstances;
• nonessential paediatric ARV formulary: everything else (not needed ARV formulary).

The optimal and limited-use paediatric ARV formularies are shown in Fig. 5 and Fig. 6.

Figure 5. IATT optimal paediatric ARV formulary, 2013.

<table>
<thead>
<tr>
<th>Drug class (or FDC)</th>
<th>Product</th>
<th>Formulation</th>
<th>Dosage</th>
<th>Rationale for list</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRI</td>
<td>AZT</td>
<td>Oral liquid</td>
<td>50 mg/5 ml</td>
<td>For use in PMTCT</td>
</tr>
<tr>
<td>NNRTI</td>
<td>EFV</td>
<td>Tablet (scored)</td>
<td>200 mg</td>
<td></td>
</tr>
<tr>
<td>NNRTI</td>
<td>NVP</td>
<td>Tablet (dispersible, scored)</td>
<td>50 mg</td>
<td></td>
</tr>
<tr>
<td>NNRTI</td>
<td>NVP</td>
<td>Oral liquid</td>
<td>50 mg/5 ml</td>
<td>For use in PMTCT</td>
</tr>
<tr>
<td>PI</td>
<td>LVP/r</td>
<td>Tablet (heat stable)</td>
<td>100 mg/25 ml</td>
<td></td>
</tr>
<tr>
<td>PI</td>
<td>LPV/r</td>
<td>Oral liquid</td>
<td>80/20 mg/ml</td>
<td></td>
</tr>
<tr>
<td>FDC</td>
<td>AZT/3TC</td>
<td>Tablet (dispersible, scored)</td>
<td>60/30 mg</td>
<td></td>
</tr>
<tr>
<td>FDC</td>
<td>AZT/3TC/NVP</td>
<td>Tablet (dispersible, scored)</td>
<td>60/30/50 mg</td>
<td></td>
</tr>
<tr>
<td>FDC</td>
<td>ABC/3TC</td>
<td>Tablet (dispersible, scored)</td>
<td>60/30 mg</td>
<td></td>
</tr>
<tr>
<td>FDC</td>
<td>ABC/3TC/AZT</td>
<td>Tablet (non-dispersible, scored)</td>
<td>60/30/60 mg</td>
<td></td>
</tr>
</tbody>
</table>
2. Vincent Habiyambere (HIV Technologies and Commodities, WHO) presented the results of the 2013 WHO survey on ARV use for children, and trends of pediatric regimens and APIs since 2006. The preliminary results indicated that 95.5% of children in low- and middle-income countries were on first-line ART regimens by the end of 2012, and that 4.4% of children were using second-line ART regimens and 0.1% on salvage. The first- and second-line pediatric ARV regimens used in 2012 are presented in Fig. 7 and Fig. 8.

**Figure 6.** IATT limited-use paediatric ARV formulary, 2013

<table>
<thead>
<tr>
<th>Drug class (or FDC)</th>
<th>Product</th>
<th>Formulation</th>
<th>Dosage</th>
<th>Rationale for list</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRTI</td>
<td>3TC</td>
<td>Tablet (dispersible)</td>
<td>30 mg</td>
<td>To be used with TDF single formulation</td>
</tr>
<tr>
<td>NRTI</td>
<td>TDF</td>
<td>Oral powder*</td>
<td>40 mg/scoop</td>
<td>For use in special circumstances when ABC or AZT cannot be used or for patients with Hepatitis B, until an appropriate FDC becomes available</td>
</tr>
<tr>
<td>NRTI</td>
<td>TDF</td>
<td>Tablet</td>
<td>150 mg</td>
<td>See above</td>
</tr>
<tr>
<td>NRTI</td>
<td>TDF</td>
<td>Tablet</td>
<td>200 mg</td>
<td>See above</td>
</tr>
<tr>
<td>NNRTI</td>
<td>ETV</td>
<td>Tablet</td>
<td>25 mg</td>
<td>Special circumstance in 3rd line where appropriate</td>
</tr>
<tr>
<td>NNRTI</td>
<td>ETV</td>
<td>Tablet</td>
<td>100 mg</td>
<td>See above</td>
</tr>
<tr>
<td>PI</td>
<td>RTV</td>
<td>Oral liquid</td>
<td>400 mg/5 ml</td>
<td>For boosting of non-co-formulated PIs and super-boosting PI during TB co-infection</td>
</tr>
<tr>
<td>PI</td>
<td>ATV</td>
<td>Solid oral dosage form</td>
<td>100 mg</td>
<td>Use in alternative 2nd line for children over 6 years old when boosting with separate RTV is available</td>
</tr>
<tr>
<td>PI</td>
<td>ATV</td>
<td>Solid oral dosage form</td>
<td>150 mg</td>
<td>See above</td>
</tr>
<tr>
<td>PI</td>
<td>DRV</td>
<td>Tablet</td>
<td>75 mg</td>
<td>Special circumstances in 3rd where appropriate and when boosting with separate RTV is available</td>
</tr>
<tr>
<td>Integrase Inhibitors</td>
<td>RAL</td>
<td>Chewable tablet (scored)</td>
<td>100 mg</td>
<td>For use in 3rd line where appropriate</td>
</tr>
<tr>
<td>FDC</td>
<td>D4T/3TC/NVP</td>
<td>Tablet (dispersible, scored)</td>
<td>6/30/50 mg</td>
<td>Special circumstance where patients cannot be transitioned to a preferred or alternative NRTI</td>
</tr>
<tr>
<td>FDC</td>
<td>D4T/3TC</td>
<td>Tablet (dispersible, scored)</td>
<td>6/30 mg</td>
<td>See above</td>
</tr>
</tbody>
</table>

**Figure 7.** First-line regimens used in 2012 for children in lower middle-income countries: 95.5% of children on ART by end of 2012 (n = 332,034)
Figure 8. Second-line regimens used in 2012 for children in lower middle-income countries: 4.4% of children on ART (n = 15 324)

Figure 9. Market share per API for nucleoside reverse transcriptase inhibitors

3. Boniface Dongmo-Nguimfack (HIV Technologies and Commodities, WHO) presented the trends of paediatric formulations uptake from the GPRM database. The market share of AZT in 2013 was over 80% in recent transactions (Fig. 9).
4. The detailed projections and related volume of ARV demand by 2016 were presented by John Stover (Vice President, Futures Institute) on behalf of the ARV Demand Forecasting Technical Working Group. The forecasts are based on data obtained from: the annual WHO survey on ARV use; transaction data from the GPRM database; CHAI projections; UNAIDS estimates of paediatric ART needs; and the Global Fund quantification data for 2014 and 2015. UNAIDS has estimated the ART needs for children aged 0–14 years by 2020 based on three scenario:

- the “constant” scenario where prevention of mother-to-child transmission (PMTCT) remains at 64% coverage and the ART coverage remains at 35%;
- the “likely” scenario where PMTCT coverage is 88% and the ART coverage is 77%;
- the “maximum” scenario with a PMTCT coverage of 95% and an ART coverage of 100%.

UNAIDS estimates show that new HIV infections in children will continue to decline but ART needs will continue to increase due to the cumulative effect of children in need of ART, as well as the infections that will continue to occur (almost 5%) no matter how much effort of prevention the national HIV programmes can do. Based on UNAIDS estimates, 2.2 million children will need ART by 2016 and, based on the three different approaches used to produce the forecasts, only 1.08 million children are projected to be on ART in 2016.

Figure 10. Number of children on ART. Country target, linear and CHAI projections

Figure 10 shows that the need for paediatric ART is well above the current and projected future demand for ART and there is therefore ample space to develop formulations for paediatric ART.

Suggestions from the discussion

- In view of the small number of children on ART, pooled procurement could speed up the production of key products, as well as minimize the risk of stock outs.
- Projection by age group 0–3 years, 3–10 years and 10–14 years was suggested. The lack of data on the age of children using ART makes this impossible, but these data may become available in the future if national paediatric ARV reporting systems adopt these three age groups of children.
- To prevent stock outs of paediatric ARVs, it was suggested to manufacturers to maintain stock piles in their warehouses. It was mentioned that having stock piles for eventual orders is possible but the current 80% shelf life requirement is a real barrier to solving country problems. The policy brief on shelf life, accompanied by operational intervention at country level to change country procurement practices and counterproductive procurement policies requiring longer shelf life, has been discussed in early November 2013 at UNICEF in Copenhagen by the Interagency Pharmaceutical Coordination group, which consists of United Nation agencies and the Global Fund, the GAVI Alliance, the European Commission and the International Pharmaceutical Federation. Its finalization needs to be accelerated. During this forecasting meeting, the view was expressed that requiring 80% of the total shelf life for medicines that will be consumed in less than 12 months is counterproductive. Participants suggested that the Global Fund, SCMS, UNICEF and WHO work together to increase countries’
capacity and flexibility in the interpretation of their procurement guidance.

At the end of Day 1, it was clear that:

- The global ARV demand forecasts and projection scenario to 2015 show that it is possible to reach, and even go beyond, the 15 by 15 target if country ART targets become the focus for financial and technical support.
- The demand for paediatric ARV formulations will increase in the foreseeable future, even if new HIV infections decline, due to PMTCT scale-up.
- The ARV Demand Forecasting Technical Working Group is developing a longer-term perspective of drugs that will be needed in the future. There is a need to be more speculative to help manufacturers in their investment to innovate and produce new formulations.
- The IATT paediatric formulation list is welcomed as an approach to rationalize procurement of paediatric ARVs in particular, as this market is too fragmented. The pooled procurement approach proposed by the Paediatric ARV Procurement Working Group was welcomed.
- The lack of data from big ARV consumers, such as South Africa and India, needs to be addressed in future forecasts.

Session IV. Panel discussion on addressing challenges of procurement and supply chain management to improve access to ARVs: regulations, financial resources and procurement mechanisms

Chaired by David Jamieson (Deputy Director, SCMS), this session started on Day 2 and covered the following topics: regulatory and quality assurance aspects; financing and resources available to meet the global ARV demand; and procurement policies.

- Lembit Rägo (Coordinator, Quality Assurance and Safety: Medicines, Department of Essential Medicines and Health Products, WHO) presented the activities that WHO is undertaking to facilitate WHO prequalified medicines following an accelerated registration procedure at country level. The aim is to reduce the current lengthy registration procedures, thus allowing accelerated access to good-quality and sometimes lower-price medicines. Lembit Rägo gave updates on the prequalification of medicines, vaccines, and diagnostics and devices. WHO ensures that medicines procured with international funds are assessed and inspected for quality, efficacy and safety, which involves a prequalification programme for medicines (finished pharmaceutical products), prequalification of APIs, and prequalification of quality control laboratories. A prequalification programme is a powerful and effective mechanism to promote access to quality medical products. The prequalification programme is an action plan for expanding access to priority essential medicines in the following four areas: HIV/AIDS, tuberculosis, malaria and reproductive health. Diagnostics are now under the same WHO prequalification programme.

- Michael Johnson (Global Fund Attaché to the OGAC) and Christine Malati (Pharmaceutical Advisor, USAID) discussed the contribution of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to the scale-up of ART. PEPFAR continues to secure substantial resources and is working closely with national governments and donor partners such as the Global Fund to ensure coordination and maximum impact of collective investments. There is an increased focus on evidence-based interventions, including treatment and PMTCT. PEPFAR plans to shift resources to treatment to meet coverage gaps, and to maintain the scale-up in coordination with other donor partners. PEPFAR was actively engaged with WHO in creating the 2013 guidelines. Christine Malati highlighted that continued attention to efficiency as illustrated by the continued decline of costs per patient treated, will enable even greater health impacts in the future. Recently, the United States Congress passed the Bill of PEPFAR Stewardship and Oversight Act of 2013, reaffirming its strong commitment to attaining an AIDS-free generation. The Bill also extended to contribute to the Global Fund.

- Martin Auton (Senior Specialist, Lead – HIV Portfolio, Global Fund) presented the financial review of current Global Fund investments in the HIV portfolio. In 2014, pledges are expected to increase as grants are coming up for renewal and signing: US$ 15 billion is the target for HIV, tuberculosis and malaria. The Global Fund covers over 5 million of the 9.7 million people on ART. The Global Fund has large investments in ART, but at the same time the institution has encouraged domestic government contributions to ensure sustainability and to achieve the target of 15 by 15. Value for money, result-focused, transparency and efficiency continue to be the principles in Global Fund supported programmes.

- Robert Matiru (HIV Portfolio Manager, UNITAID) discussed the six strategic objectives of the UNITAID strategy 2013–2016. The various projects supported by UNITAID and partners working closely with UNITAID to fight HIV were elaborated. Various innovative mechanisms are used by UNITAID to raise funds required to support public health programmes,
including notably the air ticket levy that accounts for 65% voluntary contributions. UNITAID’s grant is mostly to low-income countries (94 countries worldwide).

- Peter Ghys (Chief, Data for Action, UNAIDS) presented the international and domestic financial outlook for ART programmes. Treatment-related expenditures accounted for 54% of HIV expenditures in 2012 and US$ 18.9 billion was available for HIV, of which domestic funding accounted for half. In the Southern African subregion (dominated by South Africa) and in the Latin American region, domestic funding for HIV/AIDS is considerably higher than international funding, while in other subregions of sub-Saharan Africa and in the Caribbean, dependency on international support for treatment is still very high. According to the new 2013 WHO guidelines, 28.6 million people in low- and middle-income countries are eligible for ART, which implies the need for additional resources. With treatment optimization, it is expected that HIV programmes will be more efficient, evidence based, and deliver better value for money services. WHO/UNAIDS will continue making the case to invest in ART by setting global targets, advocating for efficiencies, and providing guidance and technical support to countries for achieving their ART targets.

- Christopher Game (Chief Procurement Officer, Global Fund) made a presentation on the Global Fund’s procurement initiatives to improve the current situation, which shows an on time and in full (OTIF) rate of only 36.8%. Using the private sector experience of better performance on OTIF, he presented what could be learned and applied to improve the situation. He highlighted the required changes in the ways the Global Fund used to do business in order to improve the situation for better performance in supply chain management. He highlighted the major principles of the approach:
  - earlier involvement and closer collaboration with manufacturers;
  - improving our purchasing capability and changing our contracting models;
  - optimizing the international supply chain to reduce cost;
  - better planning and scheduling to support continuity of supply;
  - delivering more products at the right time and place to more people.

- Martin Auton (Senior Specialist, Lead – HIV Portfolio, Global Fund and Chair for the Paediatric ARV Procurement Working Group) presented paediatric ARVs: promoting optimal ARV formulations and coordinated procurement. He showed the role of the Paediatric ARV Procurement Working Group procurement consortium, which coordinates orders across various funding and procurement mechanism, including the Global Fund, PEPFAR/SCMS, UNICEF and UNITAID/CHAI. In 2013, 64 countries, including 51 with Global Fund grants, procured through this mechanism with shorter lead-times and more reliable supply being achieved. The 51 countries with Global Fund grants represent 29% by value of the Global Fund volumes with four other countries (Ethiopia, India, Kenya and South Africa) being responsible for the majority of the rest. The Paediatric ARV Procurement Working Group is engaging with these countries and also other funders and procurers to either participate in or align their timing with the consortium’s coordination efforts.

Suggestions from the discussion

- Innovators would like to get products faster into the markets through collaboration with regulatory authorities and suggested to meet with the WHO prequalification programme to discuss how they could increase their cooperation.

- The civil society suggested to continue collaborations with manufactures to obtain reduced prices on ARVs and diagnostics for low-income and lower middle-income countries.

- Participants noted the need to continue advocacy for increased domestic financing to ensure sustainable national HIV programmes, as well as the need for the international community to support countries in using effectively HIV-allocated funds to reach the objective of 15 million people on ART by 2015.

Session V. Looking forward

In the last session, chaired by Joseph Perriëns (Coordinator, HIV Technologies and Commodities, WHO), Meg Doherty (Coordinator, HIV Treatment and Care, WHO) presented WHO’s normative ARV agenda for 2014–2015. She mentioned that the target product profile should have the following characteristics: tolerability (low incidence of side effects and toxicities, relationship to adherence); resistance (high barrier to resistance); convenience (once-daily dosing, low pill burden, no cumbersome testing requirements); special populations (pregnant women, HIV/TB, hepatitis B virus/hepatitis C virus, coinfection and children) and affordable costs.

For first-line ART, she noted that during the Second Conference on Antiretroviral Drug Optimization, chaired by CHAI and Pangaea with WHO participation, tenofovir alafenamide/ emtricitabine or lamivudine/dolutegravir (TAF/XTC/DTG) with a target cost per person per year of US$ 50, and tenofovir alafenamide/emtricitabine or lamivudine/efavirenz (TAF/XTC/EFV) (400 mg), with a target cost per person per year of US$ 70, could be potential future alternatives to tenofovir disoproxil fumarate/emtricitabine or lamivudine/efavirenz (TDF/XTC/EFV). However, since
these drug combinations have not yet been studied nor are they available in the market, these price points and FDCs are goals for future drug optimization studies. For second-line adult ART, Meg Doherty noted that the Second Conference on Antiretroviral Drug Optimization proposed the following future optimized ARV drugs: DRV/r to replace ATV/r or LPV/r, and an FDC one pill a day second-line ART such as DRV/r/DTG at a targeted cost of US$ 250 per person per year.

Meg Doherty also discussed the Paediatric Antiretroviral Drug Optimization meeting in Dakar, which covered mainly the estimates of new HIV infection among children 0–14 years, projections of paediatric ART needs by 2020, and a review of the IATT paediatric ARV formulary list as a basis to guide countries and partners in the procurement of paediatric ARV formulations. The need for new paediatric ARV formulations was also discussed. However, in order to increase access to new ARV formulations for adults and children, there is a need to take into consideration patent and registration issues, in addition to the target product profile characteristics discussed above.

**Suggestions from the discussion**

- Robust and wider-target product profile new ARV drugs for first- and second-line ART are needed for adults and children.
- ARV manufacturers appreciated that the ARV development pipeline was discussed, as it guides them for investment in development of new ARV formulations.
- The need for support to manufacturers to do more clinical trials in paediatric ART was noted.
- The need for exchange of information on recommendations made by the Second Conference on Antiretroviral Drug Optimization and the Paediatric Antiretroviral Drug Optimization meetings was noted.
- Funding organizations were advised to increase their contributions for the production of new ARV formulations that meet the target product profile.
## ANNEX I. FINAL AGENDA

### DAY 1: Monday, 25 November 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda item</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45–09:00</td>
<td>Registration</td>
<td>All participants</td>
</tr>
</tbody>
</table>
| 09:00–09:30   | Welcoming remarks                                                            | **Hiroki Nakatani**  
  Assistant Director-General, HIV/AIDS, TB, Malaria and Neglected Tropical Diseases, WHO  
  **Mariângela Simão**  
  Director, Rights, Gender and Community Mobilization Department, UNAIDS  
  **Joseph Perriëns**  
  Coordinator, HIV Technologies and Commodities, WHO |
| 09:30–10:30   | I. Panel on achieving universal access: global guidance for innovation       | **Chair: Joseph Perriëns**  
  Coordinator, HIV Technologies and Commodities, WHO  
  **Meg Doherty**  
  Coordinator, HIV Treatment and Care, WHO  
  **Badara Samb**  
  Chief, Global Outreach and Special Initiatives, UNAIDS  
  **Discussion: questions and answers**  
  All participants                                                                                                                                 |
| 10:30–11:00   | Coffee/tea                                                                   |                                                                                                                                         |
| 11:00–13:00   | II. WHO and UNAIDS forecasts of ARV global demand 2013–2016: adults          | **Chair: Joseph Perriëns**  
  Coordinator, HIV Technologies and Commodities, WHO  
  **Vincent Habiyambere**  
  HIV Technologies and Commodities, WHO  
  **Boniface Dongmo-Nguimfack**  
  HIV Technologies and Commodities, WHO  
  **Discussion: questions and answers**  
  All participants                                                                                                                                 |
|               |                                                                              |                                                                                                                                         |
| 13:00–14:00   | Lunch break                                                                  |                                                                                                                                         |
| 14:00–16:00   | III. WHO and UNAIDS forecasts of ARV global demand 2013–2016: paediatric and global APIs demand forecast | **Chair: Joseph Perriëns**  
  Coordinator, HIV Technologies and Commodities, WHO  
  **John Stover**  
  Vice President, Futures Institute, on behalf of the ARV Demand Forecasting Technical Working Group: CHAI, SCMS, Global Fund, UNICEF, UNAIDS  
  **Discussion: questions and answers**  
  All participants                                                                                                                                 |
<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda item</th>
<th>Presenter</th>
</tr>
</thead>
</table>
| 9:00–10:30       | IV. Panel discussion on addressing challenges of procurement and supply chain to improve access to ARVs | Chair: David Jamieson
Deputy Director, SCMS, on behalf of the IATT Paediatric Working Group |
|                  | 1. Regulatory and quality assurance aspects                                  |                                                                           |
|                  | Update on WHO prequalification programme and drug regulatory strengthening: progress, challenges and way forward (20 minutes) | Lembit Rago
Head of Unit, Regulation of Medicines and other Health Technologies, Department of Essential Medicines and Health Products, WHO |
|      | 2. Financial contributions                                                   |                                                                           |
|                  | PEPFAR’s Contribution to the scale-up of ART (15 minutes)                    | Michael Johnson
Global Fund Attaché to the OGAC                                         |
|                  |                                                                              | Christine Malati
Pharmaceutical Advisor, USAID                                            |
|                  | Global Fund grants to scale up access to ART (15 minutes)                    | Martin Auton
Senior Specialist, Lead – HIV Portfolio, Global Fund                      |
|                  | UNITAID’s 2013–2016 strategy and its market-shaping role in bridging the current gap towards universal access to ARV treatment (15 minutes) | Robert Matiru
HIV Portfolio Manager, UNITAID International Drug Purchase Facility       |
<p>| 16:00–16:30      | Coffee/tea                                                                  |                                                                           |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| 10:30–11:00  | International and domestic financial outlook for ART Programmes (15 minutes)       | **Peter Ghys**  
Chief, Data for Action  
UNAIDS                                                                  |
| 11:00–11:30  | Plenary discussions                                                               | All                                                                        |
| 11:30–12:30  | 3. Procurement Initiatives                                                        |                                                                            |
|              | Evolution of Global Fund procurement strategies (20 minutes)                     | **Christopher Game**  
Chief Procurement Officer, Global Fund                                           |
|              | Paediatric ARV Procurement Working Group and coordinated ordering (20 minutes)   | **Martin Auton**  
Senior Specialist, Lead – HIV Portfolio, Global Fund and  
Chair of Paediatric ARV Procurement Working Group |
|              | Questions and answers                                                             | All participants                                                            |
| 11:30–12:30  | V. Looking forward                                                                | **Chair: Joseph Perriëns**  
Coordinator, HIV Technologies and Commodities, WHO                             |
|              | WHO’s normative agenda for 2015 (20 minutes)                                      | **Meg Doherty**  
Coordinator, HIV Treatment and Care, WHO                                        |
|              | Questions and answers (30 minutes)                                               | All participants                                                            |
| 12:30–13:30  | Closing remarks                                                                    | **Joseph Perriëns**  
Coordinator, HIV Technologies and Commodities, WHO  
**Carlos Passarelli**  
Senior Expert Treatment, Science for Action/Evidence,  
Innovation, Policy, UNAIDS                                                |
| 14:00–17:00  | Individual meetings with companies and staff from WHO, UNAIDS and other partner organizations |                                                                            |
|              | Meeting rooms located on 4th floor (D44020, D45022, D45043, D45044)               |                                                                            |
ANNEX II. LIST OF PARTICIPANTS

ACTIVE PHARMACEUTICAL INGREDIENTS ARV PRODUCERS

ANHUI BIOCHEM UNITED PHARM CO. LTD
Wang Zhe
Sales/Import & Export Department
No. 30 Hongfeng Road
Hi-Tech Development Zone
Hefei (230088)
China

DESANO PHARMACEUTICALS HOLDING CO. LTD
Jie Wang
President
No. 1479 Zhangheng Road
Zhangjiang High-tech Park
Shanghai 201203
China

LONZEAL PHARMACEUTICALS CO. LTD
Jing Zhang
Marketing Director
Splendid International Plaza
No. 1 Tenth Street Shangdi, Haidian
Beijing 100085
China

MCHEM PHARMA (GROUP) LIMITED
Jennifer Xiao
General Manager
International Marketing
20/F, Everbright Bank Bldg
81 South Hubin Road
Xiamen 361004
China

SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP CO. LTD
Jinliang Li
Vice President
Building 5, No. 1999 Zhangheng Road
Zhangjiang Hi-Tech Park
Shanghai
China

ZHEJIANG-HUAHAI PHARMACEUTICAL CO. LTD
Garret Zhang
Sales Manager
Sales Department
Shanghai Office, Xunjiao, Linhai,
Zhejiang 317024
China

GENERIC ARV PRODUCERS

ASPEN PHARMA LIMITED
Nicolaou Stavros
Senior Executive
Blg 7, Health Care Park
Woodlands Drive Woodmead Sancton
PO Box 1593 Gallo Manor
South Africa

AUROBINDO PHARMA LTD
Umesh Krishna
Associate Vice President and Business Head-Antiretrovirals
The Water Mark Building, Plot No. 11,
Sy. No. 09,
Kondapur, Hi Tech City, Hyderabad, 500084
India

CIPLA LIMITED
Rahul Lande
Export Manager
NGO and Institutional Business
289 Belasis Road, Mumbai Central
547649 Mumbai
India

EMCURE PHARMACEUTICALS LIMITED
Arun Kumar Khanna
Chief Operating Officer/Executive Director
Global HIV/AIDS Initiatives
Survey No. 255/2, Phase 1, MIDC. Hinjwadi
Pune-411 957
India

Devbalaji Utharadhi
Senior Director – Global HIV/AIDS Initiatives
Global HIV/AIDS Initiatives
Survey No 255/2, Phase 1
MIDC. Hinjwadi
Pune-411 957
India

HETERO DRUGS LIMITED
Prashant Sisodia
Export Manager
289 Belasis Road, Mumbai Central
547649 Mumbai
India
Tarang Verma
Assistant Manager, International Marketing
Hetero Labs Limited
607/608 Matharu Arcade
Subhash Road
Vileparle
Mumbai 400 057
India

Namrata Vyas
Assistant Manager
International Marketing
289 Belasis Road, Mumbai Central
547649 Mumbai
India

MYLAN LABORATORIES LIMITED
Arvind Kanda
Associate Vice President
Business Development
Plot No. 564/A/22, Road No. 92
Jubilee Hills, Hyderabad–500 034
Andhra Pradesh
India

S. Gopi Krishnan
Associate Vice President
Sales & Marketing
Plot No.564/A/22, Road No. 92
Jubilee Hills, Hyderabad–500 034
Andhra Pradesh
India

Kedar Madhekar
Senior Manager
Business Development
Plot No 564/A/22 Road No. 92
Jubilee Hills Hyd-500034
Andhra Pradesh
India

QUALITY CHEMICAL INDUSTRIES LIMITED
Michael Maynard
Business Development Manager
Luzira Industrial Park
P.O. Box 34871
Kampala
Uganda

RANBAXY LABORATORY LTD
Ravi Mehta
Head – Global ARV Business
Plot No. 90 Sector 32
Gurgaon 122001
India

Sumit Misra
General Manager
ARV Business
Plot No. 90 Sector 32
Gurgaon 122001
India

REVA PHARMA
Gurpreet Sandhu
Managing Director
7, DDA Commercial Complex
1st Floor, Panscheel Park
New Delhi – 110 017
India

STRIDES ARCOLAB LIMITED
Vinod Nair
Assistant Vice President (Marketing)
Strides Arcolab Limited
Strides House,
Bilekahalli, Bannerghatta Road
Bangalore – 560076
India

Rajesh Maheswaran
Manager – Marketing
Strides Arcolab Limited
Strides House,
Bilekahalli, Bannerghatta Road
Bangalore – 560076
India

TEVA PHARMACEUTICAL INDUSTRIES LTD.
Inon Schenker
Senior Director
P.O. Box 1142
Jerusalem 9101001
Israel

UNIVERSAL CORPORATION LIMITED
Palu Dhanani
Managing Director
Club Road, Past Kikuyu Post Office
P.O. Box 1748-00902
Kikuyu
Kenya

VARICHEM PHARMACEUTICALS
Dennis Choguya
Export Executive
194 Gleneagles Road, Willowvale
Harare
Zimbabwe
INNOVATOR ARV PRODUCERS

ABBVIE (PTY) LTD
Joshua Mugo
Tender Manager
Access To Care
219 Golf Club Terrace
Constantia Kloof 1709
Johannesburg
South Africa

Boris Renjifo
Medical Director
Global Medical Affairs Virology
Global Pharmaceutical Research and Development
D-06MQ AP3, 200 Abbott Park
Il 60064-6189
USA

JANSSEN CILAG LIMITED
Luc Denys
Senior Director
Global Access & Partnership Program
Janssen Infectious Diseases and Diagnostics
Turnhoutseweg 30
2340 Belgium

MERCK AND CO. INC.
Isabelle Girault
Executive Director
Laboratoires MSD
34 Avenue Leonard de Vinci
92418 Courbevoie Cedex
France

VIIV HEALTH CARE
Helen McDowel
Scientific Strategy Director
Global Medical Team
980 Great West Road, Brentford
Middlesex, TW8 9GS
United Kingdom

Scott Purdon
Access and Government Affairs Director
980 Great West Road, Brentford
Middlesex, TW8 9GS
United Kingdom

PARTNERS

CAMPAIGN FOR ACCESS TO ESSENTIAL MEDICINES OF MÉDECINS SANS FRONTIÈRES
Arax Bozadjian
Pharmacist – HIV Focus
Médecins Sans Frontières
Campaigns for Access to Essential Medicines
Rue de Lausanne 78 – CP 116
CH–1211 Geneva 21
Switzerland

CLINTON HEALTH ACCESS INITIATIVE (CHAI)
Geannan Camponeschi
Global Market Associate
383 Dorchester Avenue, Suite 400
Boston, MA 02127
USA

Jessica Fast
Deputy Director of Access programs
383 Dorchester Avenue, Suite 400
Boston, MA 02127
USA

Marianne Gauval
Paediatric Indication Manager
Drug Access Team
383 Dorchester Avenue, Suite 400
Boston, MA 02127
USA

Vadim Shepel
Global Market Associate
383 Dorchester Avenue, Suite 400
Boston, MA 02127
USA

DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI)
Janice Lee
Project Coordinator, Paediatric HIV programme
Ch Louis Dunant 15
1202 Geneva
Switzerland

EUROPEAN AIDS TREATMENT GROUP
Nikos Dedes
European AIDS Treatment Group
P.O. Box 60132
153 10 Athens
Greece
FUTURES INSTITUTE  
Adebiyi Adesina 
Senior Economist  
41A New London Turnpike  
Glastonbury, Connecticut 06033  
USA  

John Stover  
Vice President  
41A New London Turnpike  
Glastonbury, Connecticut 06033  
USA  

IDA FOUNDATION  
Vanessa Klaassen  
Business Manager  
HIV/AIDS and Malaria  
Slochterweg 35, 1027 AA  
Amsterdam  
The Netherlands  

INTERNATIONAL AIDS SOCIETY  
Shirin Heidari  
Senior Manager  
Research Promotion  
International AIDS Society  
Avenue de France 23  
CH-1202 Geneva  
Switzerland  

Sébastien Morin, Ph.D.  
Research Officer, Industry Liaison Forum,  
International AIDS Society  
Avenue de France 23  
CH-1202 Geneva  
Switzerland  

INTERNATIONAL TREATMENT PREPAREDNESS  
COALITION  
Kenly Sikwese  
Coordinator  
African Community Advisory Board (AFROCAB)  
25815 Chalala Woodlands  
P.O. Box 31100  
Lusaka  
Zambia  

I+SOLUTIONS  
Ard van Dongen  
Director Procurement & Supply Services  
Westdam 3B  
3441 GA Woerden  
The Netherlands  

MEDICINES PATENT POOL  
Aastha Gupta  
Business Development Manager  
Chemin Louis-Dunant 17  
1202 Geneva  
Switzerland  

Sandeep Juneja  
Business Development Director  
Chemin Louis-Dunant 17  
CH-1202 Geneva  
Switzerland  

Fernando Pascual Martinez,  
Pharmaceutical and Public Health Specialist  
Consultant  
Chemin Louis-Dunant 17  
1202 Geneva  
Switzerland  

NATIONAL DEPARTMENT OF HEALTH, SOUTH AFRICA  
Anban Pillay  
Deputy Director General  
Health Regulation and Compliance  
National Department of Health  
Pretoria  
South Africa  

OFFICE OF THE U.S. GLOBAL AIDS COORDINATOR (OGAC)  
Michael P Johnson  
Global Fund Attaché to the OGAC  
U.S. President’s Emergency Plan for AIDS Relief, S/GAC  
SA-29, 2nd Floor, Washington DC 20522-2920  
USA  

PARTNERSHIP FOR SUPPLY CHAIN MANAGEMENT (PFSCM)  
David Jamieson  
Deputy Director, Supply Chain Management System  
SCMS-PSA Pharmaceuticals  
1616 N. Fort Myer Drive 12th Floor  
Arlington, Virginia 22209–3100  
USA  

Robert Staley  
Procurement Strategic and  
Technical Manager  
1616 N. Fort Myer Drive, 12th Floor  
Arlington, Virginia 22209–3100  
USA
Stephanie Xueref
Project Director
Voluntary Pooled Procurement Mechanism (VPP)
Partnership for Supply Chain Management (PFSCM)
Agence Pont - 11 Rue de Cornavin
1201 Geneva
Switzerland

THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA
Martin Auton
Senior Specialist, Lead – HIV Product Portfolio
Sourcing and Supply Management Department
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Chemin de Blandonnet 8
1214 Vernier – Geneva
Switzerland

Christopher Game
Chief Procurement Officer
Sourcing and Supply Management Department
Chemin de Blandonnet 8
1214 Vernier – Geneva
Switzerland

Dania Ghostime
Sourcing and Supply Management Department
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Chemin de Blandonnet 8
1214 Vernier – Geneva
Switzerland

UNITAID
Carmen Perez Casas
Technical Officer
Avenue Appia 20
1211 Geneva 27
Switzerland

Robert Matiru
HIV Portfolio Manager
UNITAID International Drug Purchase Facility
Avenue Appia 20
1211 Geneva 27
Switzerland

Lorenzo Witherspoon
Supply Officer
Avenue Appia 20
1211 Geneva 27
Switzerland

UNEP
UNITED NATIONS CHILDREN’S FUND (UNICEF)
Gitanjali Sakhuja
Team Lead, HIV & Malaria Unit
United Nations Children’s Fund
2100 Copenhagen
Denmark

UNITED NATIONS DEVELOPMENT PROGRAMME (UNDP)
Guy Rino Meyers
Senior Adviser
Partnership with The Global Fund to Fight AIDS, Tuberculosis and Malaria
HIV, Health and Development Group
Bureau for Development Policy
11-13 Chemin des Anémones, Châtelaine
CH-1219 Geneva
Switzerland

UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID)
Christine Malati
Pharmaceutical Advisor
USAID - GH/OHA/SCMS
Room 5.6-170 RRB
1300 Pennsylvania Ave
Washington, D.C. 20523
USA

SECRETARIAT

JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (UNAIDS)
Peter Ghys
Chief, Data for Action
Avenue Appia, 20
CH-1211 Geneva 27
Switzerland

Carlos A. Passarelli
Senior Expert Treatment
Science for Action/Evidence, Innovation, Policy
Avenue Appia, 20
CH-1211 Geneva 27
Switzerland

Badara Samb
Chief, Global Outreach and Special Initiatives
Avenue Appia, 20
CH-1211 Geneva 27
Switzerland
Mariângela Simão  
Director  
Rights, Gender and Community Mobilization  
Avenue Appia, 20  
CH-1211 Geneva 27  
Switzerland

WORLD HEALTH ORGANIZATION (WHO)  
HEALTH SYSTEMS AND SERVICES CLUSTER

DEPARTMENT OF ESSENTIAL MEDICINES AND HEALTH PRODUCTS

Lembit Rago  
Head of Unit  
Regulation of Medicines and other Health Technologies  
20 Avenue Appia  
CH-1211 Geneva 27  
Switzerland

HIV/AIDS, TB, MALARIA AND NEGLECTED TROPICAL DISEASES CLUSTER

Hiroki Nakatani  
Assistant Director-General  
20 Avenue Appia  
CH-1211 Geneva 27  
Switzerland

DEPARTMENT OF HIV/AIDS

Meg Doherty  
Coordinator  
HIV Treatment and Care  
20 Avenue Appia  
CH-1211 Geneva 27  
Switzerland

Boniface Dongmo-Nguimfack  
HIV Technologies and Commodities  
20 Avenue Appia  
CH-1211 Geneva 27  
Switzerland

Vincent Habiyambere  
HIV Technologies and Commodities  
20 Avenue Appia  
CH-1211 Geneva 27  
Switzerland

Martina Penazzato  
Consultant  
HIV Treatment and Care  
20 Avenue Appia  
CH-1211 Geneva 27  
Switzerland

Joseph Perriëns  
Coordinator  
HIV Technologies and Commodities  
20 Avenue Appia  
CH-1211 Geneva 27  
Switzerland

Ivy Sempele  
Intern  
HIV Technologies and Commodities  
20 Avenue Appia  
CH-1211 Geneva 27  
Switzerland